Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Praxis Precision Medicines
- Study ID
- NCT06999902
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Focal Seizure
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks — DRUGOnce daily oral
- Placebo — DRUGOnce daily oral
Study Details
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
Key Dates
- Start date
- Dec 11, 2024
- Status verified
- May 2025
- Primary completion
- Nov 24, 2025
- Completion
- Dec 8, 2025
Study Design
- Enrollment
- 230 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Randomized, Double-Blind 20mg/day for 6 weeks then 30mg/day for remaining 6 weeks PRAX-628Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 20 mg of PRAX-628 for 6 weeks followed by 30 mg PRAX 628 for the remaining 6 weeks.
- Experimental: Randomized, Double-Blind PlaceboParticipants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive a matching placebo throughout the 12-week Treatment Period
Primary Outcome Measure
To evaluate the efficacy of PRAX-628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs [ Time Frame: 12 weeks ]
Central Contacts
- Head of Pharmacovigilance617-300-8460
Locations (16)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Praxis Research Site | Phoenix | Arizona | 85032 | - |
| Praxis Research Site | DeLand | Florida | 32720 | - |
| Praxis Research Site | Miami Lakes | Florida | 33016 | - |
| Praxis Research Site | Chicago | Illinois | 60640 | - |
| Praxis Research Site | Lafayette | Louisiana | 70508 | - |
| Praxis Research Site | Bethesda | Maryland | 20817 | - |
| Praxis Research Site | Chesterfield | Missouri | 63005 | - |
| Praxis Research Site | Ozark | Missouri | 65721 | - |
| Praxis Research Site | Hackensack | New Jersey | 07601 | - |
| Praxis Research Site | Middletown | New York | 10940 | - |
| Praxis Research Site | Canton | Ohio | 44718 | - |
| Praxis Research Site | Oklahoma City | Oklahoma | 73112 | - |
| Praxis Research Site | El Paso | Texas | 79912 | - |
| Praxis Research Site | Frisco | Texas | 75034 | - |
| Praxis Research Site | Round Rock | Texas | 78681 | - |
| Praxis Research Site | Seabrook | Texas | 77586 | - |
Find similar trials in Phoenix, AZ
Related Studies
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresPHASE2 · Recruiting · Rapport Therapeutics Inc. · Boise, Idaho
- Clinical Trial of Vormatrigine in Adult Patients With EpilepsyPHASE3 · Enrolling By Invitation · Praxis Precision Medicines · Miami Lakes, Florida
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1PHASE3 · Recruiting · Rapport Therapeutics Inc. · Palmdale, California
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresPHASE3 · Recruiting · Rapport Therapeutics Inc. · Bentonville, Arkansas